PPCB (NASDAQ:PPCB) Shares Scheduled to Reverse Split on Monday, May 18th

PPCB (NASDAQ:PPCB)’s stock is scheduled to reverse split on Monday, May 18th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, May 17th.

PPCB Price Performance

NASDAQ PPCB traded down $0.02 during trading hours on Thursday, hitting $0.07. The company had a trading volume of 3,387,197 shares, compared to its average volume of 1,566,648. PPCB has a 1-year low of $0.07 and a 1-year high of $10.81. The firm has a 50 day moving average of $0.11.

PPCB (NASDAQ:PPCB) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.28) earnings per share (EPS) for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded PPCB from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

PPCB Company Profile

Propanc Biopharma, Inc is a healthcare company. It focuses on the development of cancer treatments for pancreatic, ovarian and colorectal cancer primarily in Australia. The Company’s products include PRP and PRP-DCM. Propanc Biopharma, Inc, formerly known as Propanc Health Group Corporation, is based in Camberwell, Australia.